Contra-indicated in patients with a history of angioedema related to previous therapy with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
See also separate profile for valsartan.
- TRADE NAME: Entresto (Novartis)
- INDICATIONS: To reduce risk of cardiovascular death and hospitalization for heart failure in chronic heart failure
- CLASS: Angiotensin receptor neprilysin inhibitor (ARNI)
- HALF-LIFE: <12 hours
FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sacubitril/valsartan in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/05/2025
